These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37657193)

  • 1. The spectrum of MAPK-ERK pathway genomic alterations in gynecologic malignancies: Opportunities for novel therapeutic approaches.
    Nasioudis D; Fernandez ML; Wong N; Powell DJ; Mills GB; Westin S; Fader AN; Carey MS; Simpkins F
    Gynecol Oncol; 2023 Oct; 177():86-94. PubMed ID: 37657193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions.
    Nasioudis D; Gysler S; Latif N; Cory L; Giuntoli RL; Kim SH; Simpkins F; Martin L; Ko EM
    Gynecol Oncol; 2024 Jan; 180():1-5. PubMed ID: 38029652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.
    Zhao Y; Yu H; Ida CM; Halling KC; Kipp BR; Geiersbach K; Rumilla KM; Gupta S; Lin MT; Zheng G
    JAMA Netw Open; 2021 Jan; 4(1):e2035479. PubMed ID: 33507258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The extended spectrum of RAS-MAPK pathway mutations in colorectal cancer.
    Costigan DC; Dong F
    Genes Chromosomes Cancer; 2020 Mar; 59(3):152-159. PubMed ID: 31589789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next generation sequencing reveals a high prevalence of pathogenic mutations in homologous recombination DNA damage repair genes among patients with uterine sarcoma.
    Nasioudis D; Latif NA; Ko EM; Cory L; Kim SH; Martin L; Simpkins F; Giuntoli R
    Gynecol Oncol; 2023 Oct; 177():14-19. PubMed ID: 37611378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
    Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
    BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Predictive and Prognostic Role of RAS-RAF-MEK-ERK Pathway Alterations in Breast Cancer: Revision of the Literature and Comparison with the Analysis of Cancer Genomic Datasets.
    Rocca A; Braga L; Volpe MC; Maiocchi S; Generali D
    Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups.
    Egan C; Nicolae A; Lack J; Chung HJ; Skarshaug S; Pham TA; Navarro W; Abdullaev Z; Aguilera NS; Xi L; Pack S; Pittaluga S; Jaffe ES; Raffeld M
    Haematologica; 2020 Apr; 105(4):951-960. PubMed ID: 31439678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma.
    Manning-Geist B; Gordhandas S; Liu YL; Zhou Q; Iasonos A; Da Cruz Paula A; Mandelker D; Long Roche K; Zivanovic O; Maio A; Kemel Y; Chi DS; O'Cearbhaill RE; Aghajanian C; Weigelt B; Chui MH; Grisham RN
    Clin Cancer Res; 2022 Oct; 28(20):4456-4465. PubMed ID: 35443055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatic genomic landscape of East Asian epithelial ovarian carcinoma and its clinical implications from prospective clinical sequencing: A Korean Gynecologic Oncology Group study (KGOG 3047).
    Sa JK; Kim J; Kang S; Kim SW; Song T; Shim SH; Choi MC; No JH; Song JY; Kim D; Kim YM; Kim JH; Lee JW
    Int J Cancer; 2022 Oct; 151(7):1086-1097. PubMed ID: 35666535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer.
    Grisham RN; Vergote I; Banerjee S; Drill E; Kalbacher E; Mirza MR; Romero I; Vuylsteke P; Coleman RL; Hilpert F; Oza AM; Westermann A; Oehler MK; Pignata S; Aghajanian C; Colombo N; Cibula D; Moore KN; Del Campo JM; Berger R; Marth C; Sehouli J; O'Malley DM; Churruca C; Kristensen G; Clamp A; Farley J; Iyer G; Ray-Coquard I; Monk BJ
    Clin Cancer Res; 2023 Oct; 29(20):4068-4075. PubMed ID: 37581616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular diagnosis in type I epithelial ovarian cancer.
    Sadłecki P; Walentowicz-Sadłecka M; Grabiec M
    Ginekol Pol; 2017; 88(12):692-697. PubMed ID: 29303228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.
    Xing D; Suryo Rahmanto Y; Zeppernick F; Hannibal CG; Kjaer SK; Vang R; Shih IM; Wang TL
    Hum Pathol; 2017 Oct; 68():87-91. PubMed ID: 28873354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic Profiling in Patients With Malignant Peripheral Nerve Sheath Tumors Reveals Multiple Pathways With Targetable Mutations.
    Kaplan HG; Rostad S; Ross JS; Ali SM; Millis SZ
    J Natl Compr Canc Netw; 2018 Aug; 16(8):967-974. PubMed ID: 30099373
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract.
    Mirkovic J; Sholl LM; Garcia E; Lindeman N; MacConaill L; Hirsch M; Dal Cin P; Gorman M; Barletta JA; Nucci MR; McCluggage WG; Howitt BE
    Mod Pathol; 2015 Nov; 28(11):1504-14. PubMed ID: 26336887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas.
    Sundov D; Caric A; Mrklic I; Gugic D; Capkun V; Hofman ID; Mise BP; Tomic S
    Diagn Pathol; 2013 Feb; 8():21. PubMed ID: 23388101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary.
    Lin DI; Killian JK; Venstrom JM; Ramkissoon SH; Ross JS; Elvin JA
    Mod Pathol; 2021 May; 34(5):983-993. PubMed ID: 33077920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.
    Ross JS; Wang K; Gay L; Otto GA; White E; Iwanik K; Palmer G; Yelensky R; Lipson DM; Chmielecki J; Erlich RL; Rankin AN; Ali SM; Elvin JA; Morosini D; Miller VA; Stephens PJ
    JAMA Oncol; 2015 Apr; 1(1):40-49. PubMed ID: 26182302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
    Sieben NL; Macropoulos P; Roemen GM; Kolkman-Uljee SM; Jan Fleuren G; Houmadi R; Diss T; Warren B; Al Adnani M; De Goeij AP; Krausz T; Flanagan AM
    J Pathol; 2004 Mar; 202(3):336-40. PubMed ID: 14991899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.